Novel optical papillary circulation improving agents containing as the active ingredient lomerizine represented by the formula (I) or pharmacologically acceptable acid addition salts thereof. These agents, which can accelerate optical papillary blood flow while giving little or no systemic side effects such as blood-pressure decrease or elevated heart rate, are usable particularly in treating normotensive glaucoma.
